Sell — Trxc Stock Buy Or

: Under the terms of the merger agreement, all outstanding shares of ASXC were acquired for $0.35 per share in cash .

: As a result of becoming a private subsidiary of KARL STORZ, the common stock has ceased trading on the NYSE American Exchange. Historical Context (TRXC to ASXC) trxc stock buy or sell

Since the company is now , it is not possible to buy or sell shares on public markets. : Under the terms of the merger agreement,

: In March 2021, the company changed its name from TransEnterix to Asensus Surgical to align with its focus on "Performance-Guided Surgery". : In March 2021, the company changed its

: KARL STORZ acquired the company primarily for its Senhance Surgical System and the development of the next-generation LUNA™ System , aiming to integrate these into their global endoscopy portfolio.

: Leading up to its acquisition, the company reported a Q2 2024 revenue of $2.2 million but sustained a net loss of $25.7 million for the same period. Investment Outlook